Inogen (NASDAQ:INGN) Issues Earnings Results

Inogen (NASDAQ:INGN) released its quarterly earnings data on Thursday. The medical technology company reported ($0.14) earnings per share for the quarter, topping the consensus estimate of ($0.15) by $0.01, FiscalAI reports. Inogen had a negative net margin of 6.94% and a negative return on equity of 12.89%. The company had revenue of $95.08 million for the quarter, compared to analyst estimates of $95.23 million.

Here are the key takeaways from Inogen’s conference call:

• Full-year revenue guidance was reduced to $355 million–$361 million from $366 million–$373 million, reflecting ongoing U.S. direct-channel pressure and the timing of international distributor inventory purchases. Management expects third-quarter revenue to be roughly flat year over year.
• International sales increased 15% year over year to $41.3 million, marking the tenth consecutive quarter of double-digit growth. Inogen cited expansion in Eastern Europe, Latin America, and Canada as longer-term growth drivers, although some distributor purchases may be delayed in the second half.
• Profitability improved, with adjusted EBITDA rising 15% year over year to $2.4 million and adjusted gross margin expanding to 45.6%. The company raised full-year adjusted EBITDA guidance to approximately $4 million, up 48% from 2025.
• New products are gaining traction: Boxy has shipped more than 5,000 units, while Aurora CPAP mask customer accounts more than doubled sequentially. Together, Boxy and Aurora contributed slightly more than 100 basis points of second-quarter growth and are expected to accelerate in the second half.
• U.S. POC unit volume grew at a high-single-digit rate, but U.S. revenue fell 2% and rental revenue declined 12% as HMEs increasingly prescribe portable concentrators at the start of therapy, reducing the traditional rental funnel. Management is reviewing options to improve the rental business while investing in B2B sales execution.

Inogen Stock Performance

Shares of INGN stock traded down $0.44 on Friday, hitting $6.05. The company’s stock had a trading volume of 599,111 shares, compared to its average volume of 222,691. Inogen has a fifty-two week low of $5.34 and a fifty-two week high of $9.13. The company has a market capitalization of $163.83 million, a PE ratio of -6.72 and a beta of 1.55. The stock’s 50 day moving average is $6.46 and its 200-day moving average is $6.38.

Insider Activity at Inogen

In other news, EVP Boyer Jennifer M. Yi sold 10,938 shares of Inogen stock in a transaction that occurred on Wednesday, July 1st. The shares were sold at an average price of $6.60, for a total value of $72,190.80. Following the completion of the sale, the executive vice president directly owned 5,039 shares in the company, valued at approximately $33,257.40. The trade was a 68.46% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 2.50% of the company’s stock.

Institutional Investors Weigh In On Inogen

Large investors have recently bought and sold shares of the company. AQR Capital Management LLC increased its stake in Inogen by 30.1% in the first quarter. AQR Capital Management LLC now owns 564,032 shares of the medical technology company’s stock valued at $4,022,000 after acquiring an additional 130,381 shares during the last quarter. Integrated Wealth Concepts LLC bought a new stake in shares of Inogen during the 1st quarter worth $85,000. Goldman Sachs Group Inc. lifted its position in shares of Inogen by 16.9% during the 1st quarter. Goldman Sachs Group Inc. now owns 284,180 shares of the medical technology company’s stock worth $2,026,000 after buying an additional 41,002 shares during the last quarter. Jane Street Group LLC acquired a new stake in shares of Inogen in the 1st quarter valued at approximately $463,000. Finally, Geode Capital Management LLC boosted its stake in shares of Inogen by 7.9% in the 2nd quarter. Geode Capital Management LLC now owns 615,279 shares of the medical technology company’s stock valued at $4,326,000 after purchasing an additional 44,860 shares in the last quarter. 89.94% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of Inogen in a report on Wednesday. One research analyst has rated the stock with a Strong Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy”.

Inogen Company Profile

Inogen, Inc (NASDAQ: INGN) is a medical device company specializing in the development, manufacture and marketing of innovative oxygen therapy solutions. The company’s core focus is on portable oxygen concentrators (POCs) designed to support patients with chronic respiratory conditions such as chronic obstructive pulmonary disease (COPD). Inogen’s offerings aim to provide users with mobility and independence by reducing reliance on traditional compressed-gas cylinders and enabling oxygen therapy on the go.

Inogen’s flagship product line, including the Inogen One family of portable oxygen concentrators, leverages proprietary flow technology to deliver continuous and pulse-dose oxygen.